About C4 Therapeutics:                     

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
 

Job Summary

C4 Therapeutics is seeking a highly motivated and innovative scientist to apply cutting edge structural biology techniques to the discovery, characterization, and development of small molecule targeted protein degraders. You will leverage your extensive experience and in-depth knowledge of how structural biology, biochemistry, and biophysics can be creatively and successfully applied to challenging drug discovery and development efforts. You will manage external CROs to support mechanistic understanding and optimization of monovalent and bivalent molecules that promote ternary complex formation between E3 ligases and drivers of disease leading to their efficient ubiquitination and degradation.  

This role gives you the opportunity to collaborate closely with lead discovery biologists as well as computational and medicinal chemists to support a broad portfolio of heterobifunctional and molecular glue degrader projects from hit finding through hit-to-lead, and lead optimization stage. Your work will be key to the evolution and enhancement of our degrader discovery platform.

Your Role

• Maintain state-of-the-art capabilities for structural biology through managing CROs in order to support E3 ligase and therapeutic target ligand discovery and optimization, binary and ternary complex characterization and small molecule degrader design 
• Contribute to drug discovery projects using X-ray crystallography and cryo-EM techniques through management of our CRO partners 
• Contribute structural biology guidance in both the design of protein constructs used in hit identification screens and in further compound progression efforts  
• Establish and maintain strong productive relationships with strategic partners and collaborators 
• Work as a leader and colleague across functional areas to help drive structure-based drug discoveries throughout our portfolio  

Your Background

Required:

• A PhD in Structural Biology, Biophysics, or a related field with a minimum of eight years of experience in a Life Science setting; additional experience can compensate for required education 
• Deep understanding and extensive experience with X-ray crystallography
• Familiarity with in vitro biochemical and biophysical methods such as SPR, FP, FRET, ITC, and their application to structure activity relationships 
• Experience with small-molecule drug discovery and effectively introducing relevant new technologies to a company environment
• Experience in managing CROs  

Preferred:

• Experience with cryoEM and/or familiarity with other structural methods such as HDX-MS and SAXS.  
• Experience with DNA encoded library (DEL) platforms

Compensation

The base pay range for this position at commencement of employment is expected to be between $172,235 and $190,365 annually; however, base pay offered may vary depending on multiple individualized factors, including job-related knowledge, skills, and experience. 

C4 Therapeutics is an Equal Opportunity Employer.